Xeya Shatavari

Asparagus racemosus (Shatavari) root extract supports women through all of life’s cycles.

Shatavari is known as “Queen of Ayurveda” and “She with 100 husbands”. It has a long histiry of use and its use is recorded in the Rig Veda 1200-1500 BCE. Shatavari is a primary Ayurvedic female rejuvenative tonic and has a wide Use for women’s and reproductive health.

A randomised, double-blind, placebo-controlled clinical trial was conducted using Xeya Shatavari 100 mg extract vs placebo daily for 84 days. The primary endpoint was the change in ovarian volume from the baseline. Secondary outcomes included ovarian cyst size and follicle number, menstrual cycle regularity, androgen-related manifestations, anthropometric indices, hormonal parameters, insulin sensitization, and safety. After 84 days:

Ovary volume decreased: Shatavari 11.53 to 8.89 cm3 vs Placebo 11.42 to 11.25 cm3 (p < 0.0001)
Cyst size decreased: Shatavari 6.45 to 3.79 mm vs Placebo 6.62 to 6.42 mm (p < 0.0001)
Sex Hormone Binding Globulin increased: Shatavari 35.58 to 41.75 nmol/L vs Placebo 35.52 to 31.69 nmol/L (p < 0.0006)
Total Testosterone decreased: Shatavari 0.65 to 0.43 ng/mL vs Placebo 0.64 to 0.65 ng/mL (p = 0.0006)
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) decreased: Shatavari
3.29 to 2.82 vs Placebo 3.19 to 3.28 (p < 0.0001)
Body weight decreased: Shatavari 62.90 to 61.08 kg vs Placebo 63.53 to 63.29 kg (p < 0.0001)
Waist circumference decreased: Shatavari 79.84 to 78.12 cm vs Placebo 78.61 to 78.38 cm (p < 0.0001)
Hip circumference decreased: Shatavari 97.00 to 95.36 cm vs Placebo 97.03 to 96.88 cm (p < 0.0001)

A randomised, double-blind, placebo-controlled investigated the therapeutic potential of a standardised Asparagus racemosus (Shatavari) root extract (15% Shatavarins) in early perimenopausal women. It assessed the extract’s ability to alleviate vasomotor symptoms, menstrual discomfort, and hormonal dysregulation through a comprehensive evaluation of symptom scores, reproductive hormone levels, ovarian follicle counts, and patient-reported outcomes, and ensuring its safety and tolerability over a 120-day supplementation.

The study demonstrated significant efficacy in alleviating a broad spectrum of perimenopausal symptoms, including vasomotor disturbances, menstrual irregularities, hormonal imbalances, and dermatological concerns, without any adverse events. Shatavari modulated key reproductive hormones (Follicle-Stimulating Hormone (FSH), Luteinizing Hormone (LH), Anti-Müllerian Hormone (AMH), and 17β-Estradiol (E2)) and significantly increased ovarian follicle counts, suggesting improved ovarian function and potential delay of reproductive ageing.

References:

Kondamudi S, Sadu S, Deva S, Yalamanchi A, Yalamanchi A. CL22209, a standardized Asparagus racemosus root extract, demonstrates improved ovarian morphology, menstrual regularity, and metabolic parameters in women with polycystic ovary syndrome in a randomized, controlled trial. Food Nutr Res. 2025 Dec 23;69.
Yadav P et al. Clinical assessment of CL22209, a standardized proprietary extract of Asparagus racemosus, for mitigating vasomotor and menstrual symptoms in perimenopausal women: A randomized, double-blind, placebo-controlled study. Functional Foods in Health and Disease 2025; 15(7): 415-443.

For more information, contact us at info@cmgrouponline.com.au

For information purposes only. Not a substitute for medical advice. If symptoms persist, talk to a health professional. Always read the label. Follow the directions for use.